07:42 AM EDT, 09/24/2024 (MT Newswires) -- Catalyst Pharmaceuticals ( CPRX ) said Tuesday its sub-licensee in Japan, DyDo Pharma, has received approval from the Ministry of Health, Labor and Welfare for the commercialization of Firdapse tablets for the treatment of patients with Lambert-Eaton Myasthenic Syndrome, or LEMS, in Japan.

Firdapse is already approved by the Food and Drug Administration in the US for treating LEMS in adults and pediatric patients aged six and older.

LEMS is a rare autoimmune disorder characterized by muscle weakness of the limbs.